Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Max Gehrman

Orthopaedic Surgery North Myrtle Beach, SC Medical Doctor

NPI 1861846883 CMS profile 4220602

1621 Highway 17 N, North Myrtle Beach, SC 29582

Open in the dashboard

General payments

$50,802

124 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Max Gehrman of North Myrtle Beach, SC is reported in the CMS Open Payments database as having received $50,802 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $232 5
2024 General $1,498 12
2023 General $3,709 33
2022 General $42,037 66
2021 General $3,325 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Max Gehrman
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Max Gehrman were reported at $232. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Max Gehrman Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $3,325 $520 $117–$2,495 $132
2022 $42,037 $598 $128–$2,731 $149
2023 $3,709 $461 $128–$2,264 $160
2024 $1,498 $497 $134–$2,475 $164
2025 $232 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Arthrex, Inc. $26,148 41 payments
  2. Smith+Nephew, Inc. $15,040 10 payments
  3. Peerless Surgical Inc. $4,129 23 payments
  4. Stryker Corporation $2,231 22 payments
  5. Zimmer Biomet Holdings, Inc. $1,558 13 payments
  6. Novus Surgical Solutions LLC $1,224 2 payments
  7. Vericel Corporation $188 4 payments
  8. Medical Device Business Services, Inc. $125 1 payment
  9. Medtronic, Inc. $112 5 payments
  10. Globus Medical, Inc. $18 1 payment
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Grant $20,125 2 payments
  2. Education $18,100 5 payments
  3. Travel and Lodging $8,147 31 payments
  4. Food and Beverage $4,429 86 payments
Products named General payments · program years 2021–2025
  1. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $1,871 15 payments
  2. Bioinductive Implant with Arthroscopic Delivery System - Medium $1,329 5 payments
  3. Bone Anchors with Arthroscopic Delivery System $412 4 payments
  4. Comprehensive Reverse $339 3 payments
  5. MACI $188 4 payments
  6. ACUFEX $166 1 payment
  7. HEALICOIL $166 1 payment
  8. Comprehensive Shoulder System $146 1 payment
  9. Comprehensive Instruments $146 1 payment
  10. TORNIER PERFORM REVERSED GLENOID $119 1 payment
  11. Other $521 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

697

Median for Orthopedic Surgery: 203

Drug cost

$3,767

Median for Orthopedic Surgery: $1,433

Branded share of claims

12.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 70 $1,053
Meloxicam Generic 326 $850
Oxycodone Hcl Generic 80 $444
Methylprednisolone Generic 66 $417
Celecoxib Generic 21 $409
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $192
Tramadol Hcl Generic 52 $167
Mupirocin Generic 15 $112
Cyclobenzaprine Hcl Generic 12 $54
Ondansetron Hcl Generic 12 $35

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$279,792

Of which drugs: $25,619

Medicare patients

1,140

Average age 73

Services billed

5,979

662 women, 478 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 74%
Diabetes 24%
Ischemic heart disease 22%
Depression 19%
Chronic kidney disease 16%
Atrial fibrillation 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 38 59 $23,781
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 430 2,477 $1,837

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record